Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infection in infants and children

Ron Dagan, Menachem Einhorn, Ruth Lang, Avishalom Pomeranz, Baruch Wolach, Dan Miron, Raoul Raz, Arieh Weintraub, Julia Steinberger, Meir Isaachson

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

We conducted a randomized prospective multicenter study to compare the safety and efficacy of once daily oral cefixime (8 mg/kg) to twice daily oral trimethoprim/sulfamethoxazole (TMP/SMX) (8/10 mg/kg/day) for the treatment of acute urinary traet infection in children ages 6 months to 13 years. Seventy-six patients (38 in each group) were studied. Thirty-seven percent were younger than 3 years of age. Escherichia coli was the most common isolate in both groups (85%). Eighty-five percent of all Gramnegative organisms were susceptible to TMP/SMX and all were susceptible to cefixime. Seventy-two percent of all patients were febrile at the time of diagnosis. Both groups were treated for 7 to 10 days. Peripheral white blood cell.

Original languageEnglish (US)
Pages (from-to)198-202
Number of pages5
JournalPediatric Infectious Disease Journal
Volume11
Issue number3
DOIs
StatePublished - Mar 1992

Keywords

  • Cefixime
  • Trimethoprim sulfamethoxazole
  • Urinary tract infection

Fingerprint Dive into the research topics of 'Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infection in infants and children'. Together they form a unique fingerprint.

Cite this